Pan American League of Associations for Rheumatology Guidelines for the treatment of ANCA-associated vasculitis
Copyright © 2023 Elsevier Ltd. All rights reserved..
Considerable variability exists in the way health-care providers treat patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Latin America. The most frequently used treatments for ANCA-associated vasculitis are cyclophosphamide and prolonged glucocorticoid tapers; however, randomised controlled trials conducted over the past 30 years have led to the development of several evidence-based treatment alternatives for these patients. Latin America faces socioeconomic challenges that affect access to care, and the use of certain costly medications with proven efficacy ANCA-associated vasculitis is often restricted. For these reasons, the Pan American League of Associations for Rheumatology developed the first ANCA-associated vasculitis treatment guidelines tailored for Latin America. A panel of local vasculitis experts generated clinically meaningful questions related to the treatment of ANCA-associated vasculitis using the Population, Intervention, Comparator, and Outcome (PICO) format. Following the Grading of Recommendations Assessment, Development, and Evaluation methodology, a team of methodologists conducted a systematic literature review. The panel of vasculitis experts voted on each PICO question and made recommendations, which required at least 70% agreement among the voting members. 21 recommendations and two expert opinion statements for the treatment of ANCA-associated vasculitis were developed, considering the current evidence and the socioeconomic characteristics of the region. These recommendations include guidance for the use of glucocorticoids, non-glucocorticoid immunosuppressants, and plasma exchange.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
The Lancet. Rheumatology - 5(2023), 8 vom: 22. Aug., Seite e483-e494 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Magri, Sebastián Juan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Antineutrophil Cytoplasmic |
|---|
| Anmerkungen: |
Date Completed 25.01.2024 Date Revised 25.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2665-9913(23)00128-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367420813 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367420813 | ||
| 003 | DE-627 | ||
| 005 | 20240125232110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2665-9913(23)00128-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1270.xml |
| 035 | |a (DE-627)NLM367420813 | ||
| 035 | |a (NLM)38251580 | ||
| 035 | |a (PII)S2665-9913(23)00128-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Magri, Sebastián Juan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pan American League of Associations for Rheumatology Guidelines for the treatment of ANCA-associated vasculitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2024 | ||
| 500 | |a Date Revised 25.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Considerable variability exists in the way health-care providers treat patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Latin America. The most frequently used treatments for ANCA-associated vasculitis are cyclophosphamide and prolonged glucocorticoid tapers; however, randomised controlled trials conducted over the past 30 years have led to the development of several evidence-based treatment alternatives for these patients. Latin America faces socioeconomic challenges that affect access to care, and the use of certain costly medications with proven efficacy ANCA-associated vasculitis is often restricted. For these reasons, the Pan American League of Associations for Rheumatology developed the first ANCA-associated vasculitis treatment guidelines tailored for Latin America. A panel of local vasculitis experts generated clinically meaningful questions related to the treatment of ANCA-associated vasculitis using the Population, Intervention, Comparator, and Outcome (PICO) format. Following the Grading of Recommendations Assessment, Development, and Evaluation methodology, a team of methodologists conducted a systematic literature review. The panel of vasculitis experts voted on each PICO question and made recommendations, which required at least 70% agreement among the voting members. 21 recommendations and two expert opinion statements for the treatment of ANCA-associated vasculitis were developed, considering the current evidence and the socioeconomic characteristics of the region. These recommendations include guidance for the use of glucocorticoids, non-glucocorticoid immunosuppressants, and plasma exchange | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 7 | |a Antibodies, Antineutrophil Cytoplasmic |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a Ugarte-Gil, Manuel Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Brance, Maria Lorena |e verfasserin |4 aut | |
| 700 | 1 | |a Flores-Suárez, Luis Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Ávila, Daniel Gerardo |e verfasserin |4 aut | |
| 700 | 1 | |a Scolnik, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Emilia Inoue |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza, Alexandre Wagner S |e verfasserin |4 aut | |
| 700 | 1 | |a Saldarriaga-Rivera, Lina María |e verfasserin |4 aut | |
| 700 | 1 | |a Babini, Alejandra Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Zamora, Natalia V |e verfasserin |4 aut | |
| 700 | 1 | |a Felquer, María Laura Acosta |e verfasserin |4 aut | |
| 700 | 1 | |a Vergara, Facundo |e verfasserin |4 aut | |
| 700 | 1 | |a Carlevaris, Leandro |e verfasserin |4 aut | |
| 700 | 1 | |a Scarafia, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Guppy, Enrique Roberto Soriano |e verfasserin |4 aut | |
| 700 | 1 | |a Unizony, Sebastian |e verfasserin |4 aut | |
| 700 | 0 | |a Pan American League of Associations for Rheumatology |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Rheumatology |d 2019 |g 5(2023), 8 vom: 22. Aug., Seite e483-e494 |w (DE-627)NLM308660307 |x 2665-9913 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2023 |g number:8 |g day:22 |g month:08 |g pages:e483-e494 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2665-9913(23)00128-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2023 |e 8 |b 22 |c 08 |h e483-e494 | ||